Search

Your search keyword '"Wahner Hendrickson, Andrea E."' showing total 3 results
Start Over Author "Wahner Hendrickson, Andrea E." Publisher escholarship, university of california
3 results on '"Wahner Hendrickson, Andrea E."'

1. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Author

duPont, Nefertiti C, Enserro, Danielle, Brady, Mark F, Moxley, Katherine, Walker, Joan L, Cosgrove, Casey, Bixel, Kristin, Tewari, Krishnansu S, Thaker, Premal, Wahner Hendrickson, Andrea E, Rubin, Stephen, Fujiwara, Keiichi, Casey, A Catherine, Soper, John, Burger, Robert A, and Monk, Bradley J

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Ovarian Cancer, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Prevention, Patient Safety, Adenocarcinoma, Black or African American, Age Factors, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Asian, Bevacizumab, Carboplatin, Carcinoma, Endometrioid, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant, Ethnicity, Fallopian Tube Neoplasms, Female, Hispanic or Latino, Humans, Middle Aged, Neoplasm Staging, Neoplasms, Cystic, Mucinous, and Serous, Ovarian Neoplasms, Paclitaxel, Peritoneal Neoplasms, Prognosis, Proportional Hazards Models, Survival Rate, White People, Minority populations, Asian women, African American women, Elderly, Ovarian cancer, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

BackgroundAge and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.MethodsWomen with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.ResultsOne-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).ConclusionsNon-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.

Published
2022

2. PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine

Author

Wethington, Stephanie L, Wahner-Hendrickson, Andrea E, Swisher, Elizabeth M, Kaufmann, Scott H, Karlan, Beth Y, Fader, Amanda Nickles, and Dowdy, Sean C

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, BRCA1 Protein, BRCA2 Protein, DNA Repair-Deficiency Disorders, Female, Humans, Mutation, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Precision Medicine, Randomized Controlled Trials as Topic, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Published
2021

3. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).

Author

Swisher, Elizabeth M, Kwan, Tanya T, Oza, Amit M, Tinker, Anna V, Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L, Aghajanian, Carol, Konecny, Gottfried E, O'Malley, David M, Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-May, Wahner Hendrickson, Andrea E, Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S, Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H, Elvin, Julia A, Lin, Douglas I, Chambers, Setsuko K, Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L, Lin, Kevin K, and McNeish, Iain A

Subjects
Humans, Ovarian Neoplasms, Neoplasm Recurrence, Local, Platinum, Indoles, DNA-Binding Proteins, BRCA1 Protein, BRCA2 Protein, Antineoplastic Agents, DNA Methylation, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Promoter Regions, Genetic, Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial
Abstract

ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results